Great news today. Trading starts tomorrow morning
This should be a major revenue source for EVER not just for Covoid
" KONTROL'S COVID-19 TECHNOLOGY PROTOTYPE RECEIVES POSITIVE LAB TEST RESULTS
Kontrol Energy Corp.'s Kontrol BioCloud fully functioning prototype was able to operate in real-time and has received positive lab test results.
"Following lab testing, we have demonstrated that our fully operating prototype, previously announced on August 10, 2020, can detect COVID-19 specific components in air samples under a controlled experiment," says Paul Ghezzi, Chief Executive Officer of Kontrol. "This was a critical milestone that we achieved as it ensures the safety and operating capability of BioCloud and we can now move quickly to testing against the live aerosolized COVID-19 virus. We remain on track with achieving our specific milestones and anticipate live COVID-19 virus testing during the week of August 31."
The controlled testing was conducted by the lab of independent consultant, Dr. David Heinrichs, PhD (Heinrichs Laboratory) - experts in the study of Microbiology and Immunology.
Next Major Milestones
The company has now tested both its proprietary detection chamber as announced on August 19, 2020 and its fully operating prototype. Following testing with the live COVID-19 virus, the Company anticipates that it will be in a position to move to commercialization and production of operating units shortly thereafter.
We continue to fund all BioCloud technology development through internal cash generation and Kontrol will not raise capital to complete testing and pre-commercialization work.
When testing against the live COVID-19 virus the Company seeks to establish the lower detection limits of BioCloud and set final parameters for applications based on room size and number of individuals. These lower detection limits will be part of commercialization specifications.
Commercialization Plans
"We are excited to have a working prototype and a successful result given all the hard work that has gone into the BioCloud," says Gary Saunders VP of Kontrol. "We have sourced all the components required for commercialization and have our supply chain ready to go. The Canadian Government has recently announced $2 billion in federal funding to help schools reopen safely. BioCloud has the potential to be an important tool in creating safe spaces by seeking to detect for the virus and assessing the effectiveness of HVAC system improvements by continuously sampling air in real-time."
The Company anticipates a selling price in the range of $12,000 US per BioCloud unit based on the current supply chain components. The detection chamber is replaceable and represents a potential secondary source of commercialized revenue for Kontrol. Any time the detection chamber comes into contact with the COVID virus it must be disposed of safely and replaced.
New Applications beyond COVID-19
During testing the Company has determined that BioCloud has the capability to detect other airborne viruses in addition to COVID-19. This determination was made based on working with the independent lab consultants and a review of the detection mechanism and specifications. While COVID-19 is the most pressing concern for creating safe spaces, other airborne viruses may have similar characteristics that BioCloud may be able to detect.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
AI
